Amer Beitinjaneh, MD, MSc, MPH, FACP

Clinical Investigator and leader of BMT and Cellular Therapy SDG #CARTcell #BMTsm #ASTCT #lymphoma

[DAVA Oncology @DAVAOnc]

The 2026 Whistler DAVA Summit on Hematological Malignancies has come to a close. We extend our gratitude to all participants for their valuable insights, expertise, and engaging questions and answers. #DAVAWhistler

[DAVA Oncology @DAVAOnc]

Starting Now: Emerging CAR-T Therapies in T-cell Lymphomas
Moderated by: Dr. Stephen Schuster @PennMedicine
#DAVAWhistler

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

Happy to be at Dava Oncology. Next 5 years will show whether CAR-T becomes a true paradigm shift in autoimmune diseases.

[DAVA Oncology @DAVAOnc]

Anti-CD19 CAR-T demonstrates a manageable safety profile with reversible TEAEs and reductions in disease activity across SLE, SSc, and IIM; 91.6% of patients remained off therapy up to ~18 months, supporting potential for immune reset. Dr. @abeitin @umiamimedicine #DAVAWhistler

[DAVA Oncology @DAVAOnc]

Anti-CD19 CAR-T demonstrates a manageable safety profile with reversible TEAEs and reductions in disease activity across SLE, SSc, and IIM; 91.6% of patients remained off therapy up to ~18 months, supporting potential for immune reset. Dr. @abeitin @umiamimedicine #DAVAWhistler

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

Our stem cell transplant and cellular therapy program has earned designation as a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Center. At the same time, the program is expanding access to care with the opening of a new outpatient satellite at University of Miami Health System SoLé Mia. 🙌

Dr. Amer Beitinjaneh serves as Sylvester’s site PI for the NHLBI-funded BMT CTN Core Center grant. His national collaborations and long-standing work with the BMT CTN helped position Sylvester for this designation and ongoing @NIH network participation. Learn more: https://t.co/eDAkYw562N

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

Honored to be promoted to Full Professor of Medicine. I’m deeply thankful to my collaborators and colleagues for their support throughout this journey. I look forward to continuing to advance clinical care, research, and education.

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

Happy to share our NEJM publication on the FELIX study that led to the FDA approval of Obe-cel for R/R B-ALL @SylvesterCancer @UMiamiHealth

[Chenyu Lin, MD @ChenyuLinMD]

Results of the FELIX trial of obe-cel in R/R B-ALL now out @NEJM. #TcellRx #leusm

➡️ 127 pts
➡️ mEFS 11.9 mo, mOS 15.6 mo
➡️ 2.4% G3+ CRS, 7.1% G3+ ICANS!
➡️ Survival curve plateau! but limited # in longer f/u
➡️ high tumor burden still a challenge

https://t.co/mLiB1CisK2 $AUTL

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

I’m happy to have led the FELIX registrational study @SylvesterCancer that resulted in the FDA approval of obecabtagene autoleucel today for R/R B Cell ALL.

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

@MKD_BMT @BloodJournal @doctorpemm @MayoCancerCare @MDAndersonNews @Harvard Congratulations @MKD_BMT , I look forward to review the manuscript.

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

@ryangentzler @GlopesMd @StephenVLiu @theNCI congrats to You Ryan and to Rich for being part of this study. @UVACareerCenter

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

Thank U @MKD_BMT @Mohty_EBMT for the invitation to be on the faculty at the IACH meeting in Paris to share our update on the management of R/R mantle cell lymphoma. @SylvesterCancer.Truly impressed by the meeting agenda and organization. Looking forward to next year’s meeting.

[Mohamed Kharfan-Dabaja, MD, MBA @MKD_BMT]

Outstanding presentation on management of relapsed/refractory mantle cell lymphoma by @abeitin at 2024 @TheIACH @COLYMCongress in #Paris @MediHumdani @Mohty_EBMT @AnnaSureda5 @StefanoLuminari

[Lymphoma Hub @lymphomahub]

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Amer Beitinjaneh @abeitin @univmiami @SylvesterCancer discusses the management of patients with R/R mantle cell lymphoma.
They highlight the role of BTK inhibitors, CAR T-cell therapies, transplantation, and novel therapies in the R/R setting.
Follow our live feed for more updates: https://t.co/IfL3fL7eM7
#lymphoma #lymsm #MedicalCongress

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

@byrnes_diana It has been a pleasure to work alongside Dr. Burns for years, treating transplant patients. He is a bright, calm, and respectful physician.

[Trent Wang, D.O., M.P.H. @cytokinerelease]

If you are in the South Florida area, come check this dinner program out.

Thursday 9/5/24 5pm-9pm @ Sunrise, FL

@FLASCO_ORG

https://t.co/NbtNIBIYhy

[Krishna Komanduri, MD, FASTCT @drkomanduri]

@RickLin_ @ASTCT #IDTwitter #CMV #immunotherapy #tcellrx #lymphoma @SylvesterCancer @abeitin @amjimenezmd

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

@drkomanduri I didn’t know ! We should play together one day !

[Hemant S. Murthy MD, FACP @hemant_murthy]

Great speaking to @Blood_Cancers about our multi-center effort investigating outcomes of HSCT in Hepatosplenic T cell lymphoma @DholariaMD @sairah__ahmed @AlhajMoustafa @abeitin @DeepJagMD @DrAmbuj @MKD_BMT @MayoCancerCare
https://t.co/PAetZjznjt

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

@mshadman @BloodCancerJnl @MediHumdani @CIBMTR @fredhutch Congrats @mshadman and happy to contribute to this excellent CIBMTR review supporting the important role of autoHCT in selected patients.

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

Happy to see Tab-cel BLA being submitted based on the ALLELE study we presented this year. https://t.co/o7Zx9rAZts.

[Amer Beitinjaneh, MD, MSc, MPH, FACP @abeitin]

Today we celebrate our amazing TCT team ( thx to @drkomanduri ) and welcome our new Chief, Dr. Damian Green @SylvesterCancer @UMiamiHealth